Important Safety Information

Indications and clinical use:

FluMist® Quadrivalent is indicated for the active immunization of individuals 2-59 years of age against influenza caused by virus subtypes A and type B contained in the vaccine.

  • Individuals with a history of hypersensitivity, especially anaphylactic reactions to eggs, egg proteins, gentamicin, gelatin, arginine or to any other ingredient in the formulation
  • Individuals with a history of hypersensitivity to a previous influenza vaccination
Relevant warnings and precautions:
  • Individuals with severe asthma or medically-attended active wheezing in the seven days prior to vaccination
  • Individuals under the age of 18 receiving aspirin or aspirin-containing therapy
  • Individuals who have reported Guillain-Barré syndrome within six weeks of any prior influenza vaccination
  • Individuals who are immunosuppressed
  • Pregnant or nursing women
For more information:

Consult the Product Monograph at for important information relating to adverse reactions, drug interactions and dosing information. The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.